Management of the sensitized cardiac recipient: The use of plasmapheresis and intravenous immunoglobulin

Clinical Transplantation

Volumn 20, Issue 4, 2006, Pages 476-484

  Leech, S H ^a   Lopez Cepero, M ^b   LeFor, W M ^b   DiChiara, L ^b   Weston, M ^b   Furukawa, S ^a   Macha, M ^a   Singhal, A ^a   Wald, J W ^a   Nikolaidis, L A ^a   McClurken, J B ^a   Bove, A A ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TAMPA GENERAL HOSPITAL   (United States)

Author keywords

Crossmatch; Heart; Intravenous immunoglobulin; Panel reactive antibody; Plasmapheresis; Rejection; Sensitization alloantibody; Transplantation

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; OKT 3; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD GROUP TYPING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; LOG RANK TEST; MALE; MORTALITY; PLASMAPHERESIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

BIOPSY; GRAFT REJECTION; HEART TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; PLASMAPHERESIS; SURVIVAL ANALYSIS;

EID: 33745629586     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00509.x     Document Type: Article

References (22)

1. Van Buskirk AM, Wakely ME, Sirak JH, Orosz CG. Patterns of allosensitization in allograft recipients: Long-term cardiac allograft acceptance is associated with active alloantibody production in conjunction with active inhibition of alloreactive delayed-type hypersensitivity. Transplantation 1998: 65: 1115.
2. Zhai Y, Meng L, Gao F, Busuttil RW, Kupiec-Weglinski JW. Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients. J Immunol 2002: 169: 4667.
3. John R, Lietz K, Schuster M et al. Immunologic sensitization in recipients of left ventricular assist devices. J Thor Cardiovasc Surg 2003: 125: 578.
4. Kobashigawa JA, Sabad A, Drinkwater D et al. Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation? Circulation 1996: 94 (Suppl.): II294.
5. Leech SH, Mather PJ, Eisen HJ et al. Donor-specific HLA antibodies after transplantation are associated with deterioration in cardiac function. Clin Transplant 1996: 10: 639.
6. Glotz D, Haymann J-P, Sasonetti N et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulin (IVIg). Transplantation 1993: 56: 335.
7. Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994: 57: 553.
8. Leech SH, Rubin S, Eisen HJ et al. Cardiac transplantation across a positive prospective lymphocyte cross-match in sensitized recipients. Clin Transplant 2003: 17 (Suppl. 9): 17.
9. Robinson JA, Radvany RM, Mullen MG, Garrity ER, Jr. Plasmapheresis followed by intravenous immunoglobulin in presensitized patients awaiting thoracic organ transplantation. Ther Apher 1997: 1: 147.
10. Pisani BA, Mullen GM, Malinowska K et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 1999: 18: 701.
11. Ray JG, Hare DB, Pederson PD, Mullay DI. NIAID Manual of Tissue Typing Techniques 1976-1977. Bethesda, MD: National Institutes of Health, 1976.
12. Billingham ME, Cary NR, Hammond MF et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transpl 1990: 9: 587.
13. Schuurman H-J, Jambroes G, Borleffs JCC, Slootweg PJ, Gmelig Meyling FHJ, De Gast GC. Acute humoral rejection after heart transplantation. Transplantation 1988: 46: 603.
14. Hiller MC, Shulman NR. Characterization of leukocyte and platelet antigens shared by non-human primates and man. Ann N Y Acad Sci 1969: 429: 162.
15. Rodey GG (ed.) HLA Beyond Tears. 2nd edn, Ch. 4. Atlanta, GA: DeNovo Inc., 2000: 73.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958: 53: 457.
17. Partanen J, Nieminen MS, Krogerus L, Harjula AL, Mattila S. Heart transplant rejection treated with plasmapheresis. J Heart Lung Transplant 1992: 11: 301.
18. Malafa M, Mancini MC, Myles JL, Gohara A, Dickinson JM, Walsh TE. Successful treatment of acute humoral rejection in a heart transplant patient. J Heart Lung Transplant 1992: 11: 486.
19. Ratkovec RM, Hammond EH, O'Connell JB et al. Outcome of cardiac transplant recipients with a positive donor-specific crossmatch - preliminary results with plasmapheresis. Transplantation 1992: 54: 651.
20. Hodge EE, Klingman LL, Koo AP et al. Pretransplant removal of anti-HLA antibodies by plasmapheresis and continued suppression on cyclosporine-based therapy after heart-kidney transplant. Transplant Proc 1994: 26: 2750.
21. John R, Lietz K, Burke E et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999: 100 (Suppl. II): 229.
22. McIntyre JA, Higgins N, Britton R et al. Utilization of intravenous immunoglobulin to ameliorate alloantibodies in a highly sensitized patient with a cardiac assist device awaiting heart transplantation. Fluorescence-activated cell sorter analysis. Transplantation 1996: 62: 691.